Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Considerations for Maternal Weight Gain

Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data on maternal weight gain associated with ART use in pregnancy including pregnancy effects and the role of baseline maternal weight.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Released: October 12, 2021

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on maternal weight gain associated with ART use in pregnancy.

Listen as she gives her perspectives on:

  • IMPAACT 2010 data on maternal weight gain with DTG + FTC/TAF vs DTG + FTC/TDF vs EFV/FTC/TDF
  • SMARTT study data on gestational weight gain by ART class
  • Tsepamo Surveillance study data on maternal weight and birth outcomes among women receiving ART, as well as weight outcomes with DTG vs EFV
  • DHHS Perinatal Guideline recommendations on dolutegravir and maternal weight gain

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022

Clinical Care Options (CCO) presents expert faculty discussing new data from AIDS 2022, from nursing perspectives

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Allison Webel, PhD, RN Mitchell J. Wharton, PhD, RN, FNP-BC, CNS, ACRN
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Expert insights on key advances in HIV treatment from the past year, from Drs Joseph Eron, Monica Gandhi, Patrick Mallon, and Clinical Care Options (CCO)

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings